NVS
Novartis·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Strong Sell"
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
Bullish Abandoned Baby
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NVS
Novartis Ag
A Swiss leading global medicines company that develops branded and generic pharmaceuticals, consmer health products, vaccines and diagnostics
Pharmaceutical
02/29/1996
05/12/2000
New York Stock Exchange
75,883
12-31
Depository Receipts (Ordinary Shares)
Lichtstrasse 35, 4056 Basel, Switzerland
Research, develop, manufacture and sell patented medicines in the fields of cancer and blood diseases
Novartis AG was established in Switzerland on February 29, 1996. The Company is an innovative drug company engaged in the research, development, manufacturing, distribution, marketing and sales of various innovative drugs. The company's mission is to use its scientific expertise to find new ways to treat and cure diseases and reimagine medicine to improve and prolong people's lives. The company's business is divided into five organizational divisions: biomedical research, development, operations and two commercial divisions (US and International). Global functions support the work of these organizational units. The company focuses on four core therapeutic areas with strong growth potential and a large number of unmet patient needs — cardiovascular, renal and metabolism; immunology; neuroscience; and oncology.
Earnings Call
Q1/2025
Estimate EPS2.17
Actual EPS2.28
Estimate Revenue13.05B
Actual Revenue13.23B
Novartis Q1 2025: Navigating Key Contradictions in Pluvicto's Strategy, Manufacturing, and Market Potential
May 13,2025 11:09
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
NVS has released its 2025 Q3 earnings. EPS was reported at 2.25, versus the expected 2.31, missing expectations. The chart below visualizes how NVS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NVS has released its 2025 Q3 earnings report, with revenue of 14.36B, reflecting a YoY change of 9.00%, and net profit of 3.93B, showing a YoY change of 23.39%. The Sankey diagram below clearly presents NVS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
